Daxxify
Daxxify is a U.S.-approved botulinum toxin type A product with the nonproprietary name daxibotulinumtoxinA-lanm. It was developed by Revance and now sits within the Revance / Crown Laboratories corporate context following Crown’s 2025 acquisition.
Daxxify is notable because Revance describes it as a peptide-formulated botulinum toxin product. That formulation identity is important product and market context, but it should not be turned into an unsupported claim that Daxxify is safer, stronger, longer-lasting, or clinically superior across uses.
Product Identity
Section titled “Product Identity”| Field | Reference point |
|---|---|
| Brand | Daxxify |
| Nonproprietary name | DaxibotulinumtoxinA-lanm |
| Toxin type | Botulinum toxin type A |
| Developer and U.S. manufacturer | Revance Therapeutics |
| Current commercial company | Revance following Crown Laboratories’ 2025 acquisition |
| Formulation context | Described by Revance as peptide-formulated |
U.S. Label Context
Section titled “U.S. Label Context”The U.S. prescribing information gives Daxxify both aesthetic and therapeutic label anchors. The aesthetic indication is temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults. The therapeutic indication is treatment of cervical dystonia in adults.
Those labels make Daxxify more than a purely aesthetic-market entry, but they do not make its units interchangeable with other botulinum toxin products.
Market Interpretation
Section titled “Market Interpretation”Daxxify expanded the U.S. type A comparison conversation by adding a newer product with a distinctive formulation narrative and both aesthetic and therapeutic label anchors. Readers may encounter duration-focused discussion around Daxxify, but the site should keep such interpretation tied to the label and cited evidence rather than broad promotional shorthand.
Graph Connections
Section titled “Graph Connections”Daxxify sits in the same U.S. type A brand map as Botox, Dysport, Xeomin, Jeuveau, and Letybo. Revance / Crown Laboratories supplies its development and ownership history.
Several people pages separate the main Revance angles: Mark Foley for Daxxify’s approval-period leadership, Nadeem Moiz for current post-acquisition company context, Steve Kreider for commercialization, and Thomas Hitchcock, Ph.D. and Conor Gallagher, Ph.D. for innovation and science framing. Jeff Bedard explains the Crown / Revance acquisition and name-transition period, while Nick Crowe adds post-acquisition operations context. Botulinum toxin type A explains the shared biology, while immunogenicity and diffusion provide caution for common cross-product comparison claims.